TY - JOUR
T1 - Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling
T2 - Insights from the CAT-HF Trial
AU - Daubert, Melissa A.
AU - Whellan, David J.
AU - Woehrle, Holger
AU - Tasissa, Gudaye
AU - Anstrom, Kevin J.
AU - Lindenfeld, Jo Ann
AU - Benjafield, Adam
AU - Blase, Amy
AU - Punjabi, Naresh
AU - Fiuzat, Mona
AU - Oldenburg, Olaf
AU - O'Connor, Christopher M.
N1 - Funding Information:
Funding sources: The CAT-HF Trial was funded by ResMed Corp .
Funding Information:
Relationships with Industry: Duke Clinical Research Institute was the recipient of research grants from ResMed Corp. M. Daubert has received research support from ResMed Corp. D. Whellan has received consulting fees and research support from ResMed Corp. H. Woehrle was employed by ResMed and has received consulting fees and research support from ResMed Corp. K. Anstrom has received research support from ResMed Corp. J. Lindenfeld has received consulting fees and research support from ResMed Corp. A. Blase is employed by ResMed. A. Benjafield is employed by ResMed. M. Fiuzat has received consulting fees and research support from ResMed Corp. O. Oldenburg has received consulting fees and research support from ResMed Corp. C. O'Connor has received consulting fees and research support from ResMed Corp. The other authors report no relevant relationships with industry to disclose.
Publisher Copyright:
© 2018
PY - 2018/7
Y1 - 2018/7
N2 - Background: Sleep-disordered breathing (SDB), including central and obstructive sleep apnea, is a marker of poor prognosis in heart failure (HF) and may worsen cardiac dysfunction over time. Treatment of SDB with adaptive servoventilation (ASV) may reverse pathologic cardiac remodeling in HF patients. Methods: The Cardiovascular Improvements with Minute Ventilation-targeted Adaptive Servo-Ventilation Therapy in Heart Failure (CAT-HF) trial randomized patients with acute decompensated HF and confirmed SDB to either optimal medical therapy (OMT) or treatment with ASV and OMT. Patients with reduced ejection fraction (HFrEF) or preserved EF (HFpEF) were included. Echocardiograms, performed at baseline and 6 months, assessed cardiac size and function and evaluated cardiac remodeling over time. The CAT-HF trial was stopped early in response to the SERVE-HF trial, which found increased mortality among HFrEF patients with central sleep apnea treated with ASV. Results: Of the 126 patients enrolled prior to trial cessation, 95 had both baseline and 6-month echocardiograms (77 HFrEF and 18 HFpEF). Among HFrEF patients, both treatment arms demonstrated a significant increase in EF: +4.3% in the ASV group (.0004) and +4.6% in OMT alone (P =.007) and a significant decrease in LV end-systolic volume index: −9.4 mL/m 2 in the ASV group (P =.01) and −8.6 mL/m 2 in OMT alone (P =.003). Reductions in left atrial (LA) volume and E/e’ were greater in the ASV arm, whereas patients receiving OMT alone demonstrated more improvement in right ventricular function. HFpEF patients treated with ASV also had a decrease in LA size that was greater than those receiving OMT alone. Although there were significant intragroup changes within the ASV + OMT and OMT-alone groups, there were no significant intergroup differences at 6 months. Conclusions: Significant reverse LV remodeling was seen among HFrEF patients with SDB regardless of treatment allocation. Substantial reductions in LA volume among HFrEF and HFpEF patients receiving ASV suggest that ASV treatment may also improve diastolic function and warrant further investigation.
AB - Background: Sleep-disordered breathing (SDB), including central and obstructive sleep apnea, is a marker of poor prognosis in heart failure (HF) and may worsen cardiac dysfunction over time. Treatment of SDB with adaptive servoventilation (ASV) may reverse pathologic cardiac remodeling in HF patients. Methods: The Cardiovascular Improvements with Minute Ventilation-targeted Adaptive Servo-Ventilation Therapy in Heart Failure (CAT-HF) trial randomized patients with acute decompensated HF and confirmed SDB to either optimal medical therapy (OMT) or treatment with ASV and OMT. Patients with reduced ejection fraction (HFrEF) or preserved EF (HFpEF) were included. Echocardiograms, performed at baseline and 6 months, assessed cardiac size and function and evaluated cardiac remodeling over time. The CAT-HF trial was stopped early in response to the SERVE-HF trial, which found increased mortality among HFrEF patients with central sleep apnea treated with ASV. Results: Of the 126 patients enrolled prior to trial cessation, 95 had both baseline and 6-month echocardiograms (77 HFrEF and 18 HFpEF). Among HFrEF patients, both treatment arms demonstrated a significant increase in EF: +4.3% in the ASV group (.0004) and +4.6% in OMT alone (P =.007) and a significant decrease in LV end-systolic volume index: −9.4 mL/m 2 in the ASV group (P =.01) and −8.6 mL/m 2 in OMT alone (P =.003). Reductions in left atrial (LA) volume and E/e’ were greater in the ASV arm, whereas patients receiving OMT alone demonstrated more improvement in right ventricular function. HFpEF patients treated with ASV also had a decrease in LA size that was greater than those receiving OMT alone. Although there were significant intragroup changes within the ASV + OMT and OMT-alone groups, there were no significant intergroup differences at 6 months. Conclusions: Significant reverse LV remodeling was seen among HFrEF patients with SDB regardless of treatment allocation. Substantial reductions in LA volume among HFrEF and HFpEF patients receiving ASV suggest that ASV treatment may also improve diastolic function and warrant further investigation.
UR - http://www.scopus.com/inward/record.url?scp=85046709233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046709233&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2018.03.026
DO - 10.1016/j.ahj.2018.03.026
M3 - Article
C2 - 29910054
AN - SCOPUS:85046709233
SN - 0002-8703
VL - 201
SP - 40
EP - 48
JO - American heart journal
JF - American heart journal
ER -